Experimental drug combo aims to tackle tough colorectal cancer
NCT ID NCT06699836
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests whether adding leronlimab to standard chemotherapy and a targeted drug can shrink tumors or improve survival in people with a specific type of advanced colorectal cancer (MSS mCRC) that has not responded to prior treatments. About 66 adults will receive one of two doses of leronlimab alongside the standard regimen. The main goals are to see if the combination increases tumor response and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
leronlimab (PRO 140) combined with trifluridine/tipiracil and bevacizumab
What this could lead to
If successful, this could offer a new treatment option for people with a hard-to-treat form of advanced colorectal cancer that has stopped responding to other therapies.
What could go wrong
This is an early Phase 2 trial with only 66 participants, so results may not apply to everyone. The added benefit of leronlimab is unproven, and combination therapy may increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, 92618, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Norton Cancer Institute, Brownsboro Hospital Campus
Louisville, Kentucky, 40241, United States
-
Pacific Hematology Oncology Associates
San Francisco, California, 94115, United States
-
Summit Cancer Center
Spokane, Washington, 99208, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States